Innova CaptabBOM:544067 -2.34%53 ROE % is 13.97% as of Mar. 2026, which is 53% below its 10-year median of 29.62. GuruFocus rates BOM:544067 with a GF Score™ of 53/100. The stock has 6 warning signs investors should review. Among 933 Drug Manufacturers companies, Innova Captab ranks better than 75.46% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Innova Captab's annualized net income for the quarter that ended in Mar. 2026 was ₹1,523 Mil. Innova Captab's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹10,908 Mil. Therefore, Innova Captab's annualized ROE % for the quarter that ended in Mar. 2026 was 13.97%.
The historical rank and industry rank for Innova Captab's ROE % or its related term are showing as below:
BOM:544067'
s ROE % Range Over the Past 10 Years
Min: 13.75 Med: 29.62 Max: 114.61
Current: 13.76
During the past 8 years, Innova Captab's highest ROE % was 114.61%. The lowest was 13.75%. And the median was 29.62%.
BOM:544067's ROE % is ranked better than 75.46% of 933
companies
in the Drug Manufacturers industry
Industry Median: 6
vs BOM:544067: 13.76
Innova Captab (BOM:544067) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Innova Captab ROE % Related Terms
Innova Captab ROE % Historical Data
* Premium members only.
The historical data trend for Innova Captab's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's ROE % distribution charts can be found below:
* The bar in red indicates where Innova Captab's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Innova Captab (BOM:544067) has a ROE % of 13.97% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Innova Captab and its competitors. This is 53% below median its historical median of 29.62. Over the past decade, Innova Captab's ROE % has ranged from 13.75 to 114.61. According to the industry distribution chart, Innova Captab ranks #229 out of 933 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Innova Captab's ROE % too high?
Innova Captab's current ROE % of 13.97% is 53% below median its 10-year median of 29.62. Over the past 10 years, this metric has ranged from a low of 13.75 to a high of 114.61. The Drug Manufacturers industry median ROE % is 6.00. Innova Captab's value of 13.97% is 132.8% above this industry median. Based on the distribution chart, Innova Captab ranks #229 out of 933 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Innova Captab has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #229 out of 933 companies for ROE %. This places Innova Captab in the top 25% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Innova Captab's value of 13.97% is 132.8% above this benchmark. Historically, Innova Captab's own ROE % has ranged from 13.75 to 114.61 over the past decade. While the company's 10-year median is 29.62 vs. the industry median of 6.00, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current ROE % of 13.97% is 132.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current ROE % is 13.97%, which is 53% below median its own 10-year median of 29.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (BOM:544067) has a current ROE % of 13.97%. The current ROE % is 13.97%, which is 53% below median its 10-year median of 29.62 and 132.8% above the Drug Manufacturers industry median of 6.00. Innova Captab's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Innova Captab (BOM:544067), the current ROE % is 13.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
53GF Score
Get the complete analysis for BOM:544067
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544067 has been successfully added to your 
